RLMD
NASDAQ · Pharmaceuticals
Relmada Therapeutics Inc
$5.16
-0.21 (-3.91%)
Open$5.25
Previous Close$5.37
Day High$5.56
Day Low$4.97
52W High$8.00
52W Low$0.55
Volume—
Avg Volume1.20M
Market Cap518.16M
P/E Ratio—
EPS$-1.15
SectorPharmaceuticals
Analyst Ratings
Strong Buy
12 analysts
Price Target
+624.2% upside
Current
$5.16
$5.16
Target
$37.37
$37.37
$22.23
$37.37 avg
$43.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 81.98M | 84.82M | 68.85M |
| Net Income | 12.35M | 12.13M | 11.14M |
| Profit Margin | 15.1% | 14.3% | 16.2% |
| EBITDA | 16.29M | 17.92M | 12.74M |
| Free Cash Flow | 15.25M | 10.32M | 8.64M |
| Rev Growth | +24.2% | +0.2% | +22.0% |
| Debt/Equity | 0.79 | 0.99 | 1.00 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $1,185.71 | -0.52% | 41.4 | 1.11T |
| JNJ | Johnson & Johnson | $259.24 | +0.88% | 29.3 | 617.08B |
| MRK | Merck & Co. Inc. | $128.58 | +0.16% | 99.4 | 315.27B |
| PFE | Pfizer Inc. | $26.76 | +2.14% | 34.8 | 150.87B |
| BMY | Bristol-Myers Squibb Co | $64.72 | +0.89% | 14.1 | 131.10B |
| ZTS | Zoetis Inc | $72.66 | -5.97% | 12.3 | 32.39B |